$RGBP
Regen BioPharma Inc Stock $rgbp

$rgbp Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000160706223000524 Filed on November 20, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2023
Revenue	$31.64K	$59.37K	$126.6K
YoY Change	0.0%	0.0%	0.83%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$134.3K	$83.12K	$711.2K
YoY Change	-68.57%	-10.51%	137.28%
% of Gross Profit
Research & Development	$47.53K	$35.34K	$212.3K
YoY Change	-50.24%	-45.01%	34.25%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$47.53K	$118.5K	$212.3K
YoY Change	-50.24%	-24.62%	34.25%
Operating Profit	-$122.8K		-$687.0K
YoY Change	-73.53%		102.28%
Interest Expense	$17.76K	-$15.94K	$58.58K
YoY Change	2.33%	-124.43%	-57.77%
% of Operating Profit
Other Income/Expense, Net	-$227.0K	-$250.0K	$1.843M
YoY Change		449.45%	-751.86%
Pretax Income	-$349.8K	-$325.0K	$1.157M
YoY Change	-121.38%	316.54%	-52.67%
Income Tax
% Of Pretax Income
Net Earnings	-$349.8K	-$325.0K	$1.157M
YoY Change	-121.38%	316.56%	-52.67%
Net Earnings / Revenue	-1105.44%	-547.46%	913.8%
Basic Earnings Per Share	-$0.10		$0.29
Diluted Earnings Per Share	-$0.10	-$0.07	$0.29
COMMON SHARES
Basic Shares Outstanding	3.559M shares		3.537M shares
Diluted Shares Outstanding	3.596M shares		3.537M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$124.5K	$121.0K	$121.0K
YoY Change	205.6%	136.41%	136.41%
Cash & Equivalents	$124.5K	$121.0K
Short-Term Investments
Other Short-Term Assets	$5.000K	$10.00K	$10.00K
YoY Change	-73.81%	-67.69%	-67.69%
Inventory
Prepaid Expenses		$0.00
Receivables	$12.30K	$0.00	$0.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$141.8K	$131.0K	$131.0K
YoY Change	-25.97%	-61.05%	-61.05%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$17.73K	$222.6K	$222.6K
YoY Change	-92.03%	0.0%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$17.73K	$222.6K	$222.6K
YoY Change	-92.03%	0.0%	0.0%
TOTAL ASSETS
Total Short-Term Assets	$141.8K	$131.0K	$131.0K
Total Long-Term Assets	$17.73K	$222.6K	$222.6K
Total Assets	$159.5K	$353.6K	$353.6K
YoY Change	-61.48%	-36.74%	-36.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$44.18K	$29.67K	$29.67K
YoY Change	42.35%	3.04%	3.02%
Accrued Expenses	$1.663M	$1.645M	$1.645M
YoY Change	3.03%	-17.84%	-17.84%
Deferred Revenue
YoY Change
Short-Term Debt	$50.21K	$96.71K	$96.71K
YoY Change	2836.26%	5555.56%	5555.56%
Long-Term Debt Due	$509.9K	$509.9K	$509.9K
YoY Change	0.0%	-59.93%	-59.93%
Total Short-Term Liabilities	$5.247M	$5.308M	$5.308M
YoY Change	-0.98%	-38.24%	-38.24%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$154.0K	$149.6K	$149.6K
YoY Change
Total Long-Term Liabilities	$154.0K	$149.6K	$149.6K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.247M	$5.308M	$5.308M
Total Long-Term Liabilities	$154.0K	$149.6K	$149.6K
Total Liabilities	$5.401M	$5.458M	$5.458M
YoY Change	1.93%	-36.5%	-36.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$20.10M	-$19.75M
YoY Change	4.3%	-5.53%
Common Stock	$376.00	$352.00
YoY Change	-99.93%	-99.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.241M	-$5.104M	-$5.104M
YoY Change
Total Liabilities & Shareholders Equity	$159.5K	$353.6K	$353.6K
YoY Change	-61.48%	-36.74%	-36.74%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2023
OPERATING ACTIVITIES
Net Income	-$349.8K	-$325.0K	$1.157M
YoY Change	-121.38%	316.56%	-52.67%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$162.3K	-$23.92K	-$173.9K
YoY Change	1451.52%	-71.95%	-128.66%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$165.8K	143.8K	$243.8K
YoY Change		28650.0%	-359.21%
NET CHANGE
Cash From Operating Activities	-$162.3K	-23.92K	-$173.9K
Cash From Investing Activities
Cash From Financing Activities	$165.8K	143.8K	$243.8K
Net Change In Cash	$3.461K	119.8K	$69.83K
YoY Change	-133.08%	-300.42%	-110.33%
FREE CASH FLOW
Cash From Operating Activities	-$162.3K	-$23.92K	-$173.9K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001589150
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023Q3	RGBP	Convertible Notes Payable Related Parties Less Unamortized Discount Noncurrent ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscountNoncurrent		usd
CY2023	RGBP	Increase Decrease In Contributed Capital IncreaseDecreaseInContributedCapital		usd
CY2022	RGBP	Increase Decrease In Contributed Capital IncreaseDecreaseInContributedCapital		usd
CY2023	RGBP	Securities Accepted As Compensation SecuritiesAcceptedAsCompensation		usd
CY2022	RGBP	Securities Accepted As Compensation SecuritiesAcceptedAsCompensation		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	333-191725
CY2023	dei	Entity Registrant Name EntityRegistrantName	REGEN BIOPHARMA, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-5192997
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	4700 Spring Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 304
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	La Mesa
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	91942
CY2023	dei	City Area Code CityAreaCode	619
CY2023	dei	Local Phone Number LocalPhoneNumber	722 5505
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023Q1	dei	Entity Public Float EntityPublicFloat	6592681	usd
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3558861	shares
CY2023	dei	Auditor Name AuditorName	BF Borgers CPA PC
CY2023	dei	Auditor Firm AuditorFirmId	5041
CY2023	dei	Auditor Location AuditorLocation	Lakewood, CO
CY2023Q3	us-gaap	Cash Cash	121037	usd
CY2022Q3	us-gaap	Cash Cash	51204	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	254273	usd
CY2023Q3	RGBP	Notes Receivable Related Party Current NotesReceivableRelatedPartyCurrent	0	usd
CY2022Q3	RGBP	Notes Receivable Related Party Current NotesReceivableRelatedPartyCurrent	0	usd
CY2023Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	0	usd
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	20945	usd
CY2023Q3	us-gaap	Prepaid Rent PrepaidRent	10000	usd
CY2022Q3	us-gaap	Prepaid Rent PrepaidRent	10000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	131037	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	336422	usd
CY2023Q3	RGBP	Investment Securities Related Party InvestmentSecuritiesRelatedParty	222580	usd
CY2022Q3	RGBP	Investment Securities Related Party InvestmentSecuritiesRelatedParty	222580	usd
CY2023Q3	us-gaap	Other Assets OtherAssets	222580	usd
CY2022Q3	us-gaap	Other Assets OtherAssets	222580	usd
CY2023Q3	us-gaap	Assets Assets	353617	usd
CY2022Q3	us-gaap	Assets Assets	559002	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	29674	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	28799	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	95710	usd
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	710	usd
CY2023Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4241	usd
CY2022Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	4241	usd
CY2023Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	342588	usd
CY2022Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	689785	usd
CY2023Q3	RGBP	Accrued Payroll Current AccruedPayrollCurrent	1256630	usd
CY2022Q3	RGBP	Accrued Payroll Current AccruedPayrollCurrent	1266679	usd
CY2023Q3	RGBP	Other Accrued Expenses OtherAccruedExpenses	41423	usd
CY2022Q3	RGBP	Other Accrued Expenses OtherAccruedExpenses	41423	usd
CY2023Q3	us-gaap	Bank Overdrafts BankOverdrafts	1000	usd
CY2022Q3	us-gaap	Bank Overdrafts BankOverdrafts	1000	usd
CY2023Q3	RGBP	Due To Investor DueToInvestor	20000	usd
CY2022Q3	RGBP	Due To Investor DueToInvestor	20000	usd
CY2023Q3	RGBP	Unearned Income UnearnedIncome	1591731	usd
CY2022Q3	RGBP	Unearned Income UnearnedIncome	1718290	usd
CY2023Q3	RGBP	Unearned Income Related Party UnearnedIncomeRelatedParty	15126	usd
CY2022Q3	RGBP	Unearned Income Related Party UnearnedIncomeRelatedParty	0	usd
CY2023Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	1400000	usd
CY2022Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	3551793	usd
CY2023Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	499880	usd
CY2022Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1262340	usd
CY2023Q3	RGBP	Convertible Notes Payable Related Parties Less Unamortized Discount ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount	10000	usd
CY2022Q3	RGBP	Convertible Notes Payable Related Parties Less Unamortized Discount ConvertibleNotesPayableRelatedPartiesLessUnamortizedDiscount	10000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5308003	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8595061	usd
CY2023Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	149614	usd
CY2022Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	149614	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	usd
CY2023Q3	us-gaap	Liabilities Liabilities	5457617	usd
CY2022Q3	us-gaap	Liabilities Liabilities	8595061	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5800000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5800000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3354866	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3354866	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3506366	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3506366	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	352	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	503150	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	800000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	800000000	shares
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	13908141	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11581499	usd
CY2023Q3	us-gaap	Other Additional Capital OtherAdditionalCapital	736326	usd
CY2022Q3	us-gaap	Other Additional Capital OtherAdditionalCapital	736326	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19748863	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20905369	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5104000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8036059	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	353617	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	559002	usd
CY2023	us-gaap	Revenues Revenues	126560	usd
CY2022	us-gaap	Revenues Revenues	125517	usd
CY2023	RGBP	Revenues Related Party RevenuesRelatedParty	110000	usd
CY2022	RGBP	Revenues Related Party RevenuesRelatedParty	110000	usd
CY2023	RGBP	Total Revenues TotalRevenues	236560	usd
CY2022	RGBP	Total Revenues TotalRevenues	235517	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	212297	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	158138	usd
CY2023	RGBP	Research And Development Related Party ResearchAndDevelopmentRelatedParty	0	usd
CY2022	RGBP	Research And Development Related Party ResearchAndDevelopmentRelatedParty	117250	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	44975	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28055	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	606237	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	221679	usd
CY2023	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	60000	usd
CY2022	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	50000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	923509	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	575122	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-686950	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-339605	usd
CY2023	us-gaap	Interest And Other Income InterestAndOtherIncome	0	usd
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome	455	usd
CY2023	us-gaap	Interest Expense InterestExpense	58584	usd
CY2022	us-gaap	Interest Expense InterestExpense	138720	usd
CY2023	RGBP	Interest Expense Attributable To Amortization Of Discount InterestExpenseAttributableToAmortizationOfDiscount	-864	usd
CY2022	RGBP	Interest Expense Attributable To Amortization Of Discount InterestExpenseAttributableToAmortizationOfDiscount	-71067	usd
CY2023	us-gaap	Income Tax Examination Penalties Expense IncomeTaxExaminationPenaltiesExpense	-0	usd
CY2022	us-gaap	Income Tax Examination Penalties Expense IncomeTaxExaminationPenaltiesExpense	300000	usd
CY2023	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	0	usd
CY2022	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	31433	usd
CY2023	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	usd
CY2022	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-1828	usd
CY2023	RGBP	Gain Loss On Derecognition Of Accounts Payable GainLossOnDerecognitionOfAccountsPayable	0	usd
CY2022	RGBP	Gain Loss On Derecognition Of Accounts Payable GainLossOnDerecognitionOfAccountsPayable	62700	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2151755	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	3340683	usd
CY2023	RGBP	Financing Fees FinancingFees	-250000	usd
CY2022	RGBP	Financing Fees FinancingFees	-45500	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1150	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-95019	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1843456	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2783136	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	1156507	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	2443531	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1023508	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2227034	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.7102
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.7102
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3536963	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3536963	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3135846	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3135846	shares
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-13485877	usd
CY2021Q4	RGBP	Shares Issued For Debt Amount SharesIssuedForDebtAmount	100000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value SharesIssuedForInterestValue	26662	usd
CY2021Q4	RGBP	Shares Issued For Debt1 Amount SharesIssuedForDebt1Amount	100000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value1 SharesIssuedForInterestValue1	38837	usd
CY2021Q4	RGBP	Shares Issued For Debt2 Amount SharesIssuedForDebt2Amount	50000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value2 SharesIssuedForInterestValue2	19603	usd
CY2021Q4	RGBP	Shares Issued For Debt3 Amount SharesIssuedForDebt3Amount	50000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value3 SharesIssuedForInterestValue3	18575	usd
CY2021Q4	RGBP	Shares Issued For Interest Value4 SharesIssuedForInterestValue4	75000	usd
CY2021Q4	RGBP	Shares Issued For Debt4 Amount SharesIssuedForDebt4Amount	32075	usd
CY2021Q4	RGBP	Shares Issued For Interest Value5 SharesIssuedForInterestValue5	25000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value6 SharesIssuedForInterestValue6	10356	usd
CY2021Q4	RGBP	Shares Issued For Debt5 Amount SharesIssuedForDebt5Amount	25000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value7 SharesIssuedForInterestValue7	8883	usd
CY2021Q4	RGBP	Shares Issued For Debt6 Amount SharesIssuedForDebt6Amount	50000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value8 SharesIssuedForInterestValue8	23369	usd
CY2021Q4	RGBP	Shares Issued For Debt7 Amount SharesIssuedForDebt7Amount	100000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value9 SharesIssuedForInterestValue9	39808	usd
CY2021Q4	RGBP	Shares Issued For Debt8 Amount SharesIssuedForDebt8Amount	40000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value10 SharesIssuedForInterestValue10	14192	usd
CY2021Q4	RGBP	Shares Issued For Debt9 Amount SharesIssuedForDebt9Amount	50000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value11 SharesIssuedForInterestValue11	19012	usd
CY2021Q4	RGBP	Shares Issued For Debt10 Amount SharesIssuedForDebt10Amount	10964	usd
CY2021Q4	RGBP	Shares Issued For Debt11 Amount SharesIssuedForDebt11Amount	25000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value12 SharesIssuedForInterestValue12	11527	usd
CY2021Q4	RGBP	Shares Issued For Debt12 Amount SharesIssuedForDebt12Amount	60000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value13 SharesIssuedForInterestValue13	25440	usd
CY2021Q4	RGBP	Shares Issued For Debt13 Amount SharesIssuedForDebt13Amount	25000	usd
CY2021Q4	RGBP	Shares Issued For Interest Value14 SharesIssuedForInterestValue14	10625	usd
CY2021Q4	us-gaap	Profit Loss ProfitLoss	2644980	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-9755969	usd
CY2022Q1	RGBP	Shares Issued For Debt Amount SharesIssuedForDebtAmount	48420	usd
CY2022Q1	RGBP	Shares Issued For Interest Value SharesIssuedForInterestValue	39708	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-67081589	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-76749430	usd
CY2022Q2	RGBP	Shares Issued For Debt Amount SharesIssuedForDebtAmount	218617	usd
CY2022Q2	RGBP	Shares Issued For Interest Value SharesIssuedForInterestValue	1701	usd
CY2022Q2	RGBP	Shares Issued For Debt1 Amount SharesIssuedForDebt1Amount	550161	usd
CY2022Q2	RGBP	Shares Issued For Interest Value1 SharesIssuedForInterestValue1	1500	usd
CY2022Q2	RGBP	Shares Issued For Debt2 Amount SharesIssuedForDebt2Amount	334800	usd
CY2022Q2	RGBP	Shares Issued For Debt3 Amount SharesIssuedForDebt3Amount	334800	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	66958167	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-8349684	usd
CY2022Q3	RGBP	Shares Issued For Debt Amount SharesIssuedForDebtAmount	132650	usd
CY2022Q3	RGBP	Shares Issued For Interest Value SharesIssuedForInterestValue	32950	usd
CY2022Q3	RGBP	Shares Issued For Debt1 Amount SharesIssuedForDebt1Amount	180552	usd
CY2022Q3	RGBP	Shares Issued For Expenses SharesIssuedForExpenses	45500	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-78027	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-8036059	usd
CY2022Q4	RGBP	Preferred Shares Issued For Nonemployee Services PreferredSharesIssuedForNonemployeeServices	300000	usd
CY2022Q4	RGBP	Preferred Shares Issued For Debt PreferredSharesIssuedForDebt	761500	usd
CY2022Q4	RGBP	Preferred Shares Issued For Interest PreferredSharesIssuedForInterest	380262	usd
CY2022Q4	RGBP	Common Shares Issued For Interest CommonSharesIssuedForInterest	25369	usd
CY2022Q4	RGBP	Preferred Shares Issued For Nonemployee Services1 PreferredSharesIssuedForNonemployeeServices1	48372	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	1635730	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4884827	usd
CY2023Q1	RGBP	Common Shares Issued Pursuant To Round Up Provision March62023 Reverse Stock Split CommonSharesIssuedPursuantToRoundUpProvisionMarch62023ReverseStockSplit	0	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	10050	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-54978	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-4929755	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-99218	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-5028973	usd
CY2023Q3	RGBP	Common Shares Issued For Financing Expenses CommonSharesIssuedForFinancingExpenses	250000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-325027	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-5104000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	1156507	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	2443531	usd
CY2023	RGBP	Common Stock Issued For Expenses CommonStockIssuedForExpenses	-250000	usd
CY2022	RGBP	Common Stock Issued For Expenses CommonStockIssuedForExpenses	-45500	usd
CY2023	RGBP	Preferred Stock Issued As Compensation PreferredStockIssuedAsCompensation	-348372	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	864	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	71067	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	875	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-62705	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-254272	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	41082	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	58583	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	109747	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-20947	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-17199	usd
CY2023	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-2151755	usd
CY2022	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-3340683	usd
CY2023	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-111433	usd
CY2022	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-125517	usd
CY2022	RGBP	Increase Decrease In Penalties IncreaseDecreaseInPenalties	300000	usd
CY2022	us-gaap	Increase Decrease In Notes Receivables IncreaseDecreaseInNotesReceivables	-5396	usd
CY2022	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-230	usd
CY2023	RGBP	Gain Loss On Forgiveness Of Debt GainLossOnForgivenessOfDebt	1150	usd
CY2022	RGBP	Increase Decrease In Loss On Sale Of Investment Securities IncreaseDecreaseInLossOnSaleOfInvestmentSecurities	-1828	usd
CY2022	RGBP	Unrealized Lossgain On Investment Securities UnrealizedLossgainOnInvestmentSecurities	31433	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-173917	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-606921	usd
CY2022	RGBP	Increasedecrease In Sale Of Investment Securities IncreasedecreaseInSaleOfInvestmentSecurities	-25000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25000	usd
CY2022	RGBP	Increase Decrease In Convertible Notes Payable IncreaseDecreaseInConvertibleNotesPayable	-94535	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	243750	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	499	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	243750	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-94036	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	69833	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-675957	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51204	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	727162	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	121037	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51204	usd
CY2022	RGBP	Common Shares Issued For Debt CommonSharesIssuedForDebt	2510964	usd
CY2023	RGBP	Preferred Share Issued For Debt PreferredShareIssuedForDebt	761500	usd
CY2022	RGBP	Preferred Share Issued For Debt PreferredShareIssuedForDebt	75000	usd
CY2022	RGBP	Cash Paid For Interest CashPaidForInterest	27473	usd
CY2023	RGBP	Common Shares Issued For Interests CommonSharesIssuedForInterests	25369	usd
CY2022	RGBP	Common Shares Issued For Interests CommonSharesIssuedForInterests	342329	usd
CY2023	RGBP	Preferred Shares Issued For Interests PreferredSharesIssuedForInterests	380262	usd
CY2022	RGBP	Preferred Shares Issued For Interests PreferredSharesIssuedForInterests	33994	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0529	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	9.2038	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	1	pure
CY2022	us-gaap	Advertising Expense AdvertisingExpense	0	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	0	usd
	RGBP	Net Income Loss Since Inception NetIncomeLossSinceInception	19748863	usd
CY2023Q3	RGBP	Common Stock Equals Percentage CommonStockEqualsPercentage	0.80	pure
CY2023Q3	RGBP	Common Stock Requested Percentage CommonStockRequestedPercentage	2	pure
CY2023Q3	RGBP	Average Daily Traded Value AverageDailyTradedValue	250000	usd
CY2023Q3	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	175000	usd
CY2023Q3	RGBP	Original Issue Discount OriginalIssueDiscount	26250	usd
CY2023	us-gaap	Debt Instrument Redemption Price Percentage Of Principal Amount Redeemed DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed	0.10	pure
CY2023	RGBP	Guaranteed Interest GuaranteedInterest	26250	usd
CY2023	RGBP	Guaranteed Interest On Principal Amount Due GuaranteedInterestOnPrincipalAmountDue	28750	usd
CY2023	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2025-03-12
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5800000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3506366	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3506366	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	800000000	shares
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4147261	usd
CY2023Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-0	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4147261	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4147261	usd
CY2023Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	-0	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4147261	usd
CY2023Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	19748863	usd
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1 for 1500

Files In Submission

Name	View Source	Status
0001607062-23-000524-index-headers.html	Edgar Link	pending
0001607062-23-000524-index.html	Edgar Link	pending
0001607062-23-000524.txt	Edgar Link	pending
0001607062-23-000524-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex31_2.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
ex32_2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgbp-20230930.xsd	Edgar Link	pending
rgbp093023form10k.htm	Edgar Link	pending
Show.js	Edgar Link	pending
rgbp-20230930_cal.xml	Edgar Link	unprocessable
rgbp-20230930_lab.xml	Edgar Link	unprocessable
rgbp-20230930_def.xml	Edgar Link	unprocessable
rgbp-20230930_pre.xml	Edgar Link	unprocessable
rgbp093023form10k_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGBP
Regen BioPharma Inc Stock $rgbp

2023 Q4 Form 10-K Financial Statement

#000160706223000524 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGBP Regen BioPharma Inc Stock $rgbp

2023 Q4 Form 10-K Financial Statement

#000160706223000524 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGBP
Regen BioPharma Inc Stock $rgbp